Cost-effectiveness analysis of metformin or pioglitazone combined with sulfonylurea in type 2 diabetes mellitus in Japan

Journal of the Japan Diabetes Society

Volumn 53, Issue 7, 2010, Pages 469-475

  Ikeda, Shunya ^a   Kobayashi, Makoto ^b  

^a INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^b Crecon Research and Consulting Inc   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956355592     PISSN: 0021437X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Clarke PM. Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, Matthews DR, Stratton IM, Holman RR; UK Prospective Diabetes Study (UKPDS) Group (2004) A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 47 (10): 1747-1759 (Pubitemid 40022410)
2. Briggs A, Sculpher M (1998) An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 13 (4): 397-409 (Pubitemid 28140699)
3. Watanabe J, Iwabuchi K, Koseki Y, Fukuchi M, Shinozaki T, Miura M, Komáru T, Kagaya Y, Shirato K, Kitaoka S, Ishide N, Takishima T (2001) Declining trend in the in-hospital case-fatality rate from acute myocardial infarction in Miyagi Prefecture from 1980 to 1999. Jpn Circ J 65 (11): 941-946
4. http://www.akitaepid.net/download/%e8%84%b3%e5%8d%92%e4%b8%a d%e7%b5%b1%e8%a8%88.pdf
5. http://www.mhlw.go.jp/toukei/saikin/hw/life/life07/inde. html
6. Sone H, Katagiri A, Ishibashi S, Abe R, Saito Y, Murase T, Yamashita H, Yajima Y, Ito H, Ohashi Y, Akanuma Y, Yamada N; JDC Study Group (2002) Effects of lifestyle modifications on patients with type 2 diabetes: the Japan Diabetes Complications Study (JDCS) study design, baseline analysis and three yearinterim report. Horm Metab Res 34 (9): 509-515 (Pubitemid 35192238)
7. Evans E, Imanaka Y, Sekimoto M, Ishizaki T, Hayashida K, Fukuda H, Oh EH (2007) Risk adjusted resource utilization for AMI patients treated in Japanese hospitals. Health Econ 16 (4): 347-359 (Pubitemid 46566851)
8. Inomata T, Izumi T, Kobayashi M (2004) Costeffectiveness analysis of Carvedilol for the treatment of chronic heart failure in Japan. Circ J 68 (1): 3540
9. Yoneda Y. Okuda S, Hamada R. Toyota A, Gotoh J, Watanabe M, Okada Y, Ikeda K, Ibayashi S, HasegawaY (2005) Hospital cost of ischemic stroke and intracerebral hemorrhage in Japanese stroke centers. Health Policy 73 (2): 202-211 (Pubitemid 40835902)
10. http://www.mhlw.go.Jp/toukei/saikin/hw/sinryo/tyosa07/index.html
11. Clarke P, Gray A, Holman R (2002) Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 22 (4): 340-349 (Pubitemid 34791321)
12. Lee AJ, Morgan CL, Conway P, Currie CJ (2005) Characterisation and comparison of health-related quality of life for patients with renal failure. Curr Med Res Opin 21 (11): 1777-1783 (Pubitemid 41667245)
13. Borgström F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O, Abdon P, Ornstein E, Lunsjö K, Thorngren KG, Sernbo I, Rehnberg C, Jönsson B (2006) Costs and quality of life associated with osteoporosis-related fractures in Swaden. Osteoporos Int 17 (5): 637-650
14. Dolan P, Gudex C, Kind P, Williams A (1995) A social tariff for EuroQOL: Results from a UK general population survey. http://www.york.ac.uk/inst/che/pdf/ DP138.pdf
15. Nagasaka S, Aiso Y, Yoshizawa K, Ishibashi S (2004) Comparison of pioglitazone and metformin efficacy using homeostasis model assessment Diabet Med 21 (2): 136-141
16. Takeda Pharmaceuticals (2007) Observation of an increased incidence of fractures in female patients who received long-term treatment with ACTOS (pioglita-zone hydrochloride) tablets for type 2 diabetes mellitus [Letter to Health Care Providers]. http://www.fdagov/downloads/Safety/MedWatch/ Safetylnformati on/SafetyAlertsforHumanMedicalProducts/UCM153 896.pdf
17. http://www.mhlw.go.jp/houdou/2008/12/h1225-5.html
18. http://www.mhlw.go.jp/toukei/saikin/hw/k-iryohi/05/index.html
19. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive investigators (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): a randomised controlled trial. Lancet 366:1279-1289 (Pubitemid 41416583)
20. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochellière R, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, Tuzcu EM; PERISCOPE Investigators (2008) Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299 (13): 1561-1573 (Pubitemid 351482795)